{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000121","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-09-16T20:32:09+00:00","discovered_at":"2026-09-16T20:33:01.556408+00:00","generated_at":"2026-09-16T20:33:05.993167+00:00","sec_items":["8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Halozyme announces $1.05B convertible notes offering due 2033","bullets":["Offering of $1.05B aggregate principal of convertible senior notes due 2033, unsecured, semi-annual interest, maturing Oct 1, 2033.","13-day option for initial purchasers to buy up to $150M additional notes, for potential total of $1.2B.","Proceeds to fund capped call transactions, repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes, and general corporate purposes.","Capped calls intended to reduce dilution; concurrent note repurchases may affect common stock price."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000121","json":"https://secwatch.observer/filing/0001159036-26-000121.json","markdown":"https://secwatch.observer/filing/0001159036-26-000121.md","text":"https://secwatch.observer/filing/0001159036-26-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/0001159036-26-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/halo-20260916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T20:33:05.993167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}